When activated effectively, pharmaceutical marketing media strategies can lead to better outcomes and, consequently, improved health for individuals and communities.
In Part 1, we established that pharma marketing succeeds when strategy is designed to learn. The next challenge is harder: deciding what success actually looks like. The shift from campaign execution to outcome systems changes how we define success.
This post will outline the next two principles I stand by, and the last post will present the fifth principle.
3. Measure outcomes, not engagement.
Everyone agrees with this concept. Very few organizations bring it to life well. At MERGE, we view outcomes as both a gradient and a system. They aren’t a single, static goal, but are a continuously evolving, interconnected journey. The right outcome metric depends on category dynamics, time to script, and scale of investment.
For fast-moving categories such as vaccines or acute therapies that patients take immediately or for a short time, “new to prescription” can be a viable primary optimization metric. Volume and signal density are often sufficient to support deterministic optimization. There’s enough data to trust the information and calculate the best marketing tactic, incentivizing more doctors to select your particular brand.
Many therapies like those for chronic conditions do not behave this way. The pharmacy fulfillment time may be six months, a year, or longer. In those cases, waiting for downstream prescription data alone is not practical.
This is where leading indicators matter. Audience quality is one such indicator, but it is frequently misunderstood. Audience quality is a density metric, not a reach metric. It helps confirm that spend is concentrated where likelihood of conversion is higher. It does not indicate whether enough people are being reached to move the business.
Let’s say every single person who sees your ad is a perfect customer, but if that means only five or even 10 people see it, your business won’t grow. Likewise, an audience of 100 highly qualified patients may look attractive. It may also be prohibitively expensive to activate at scale.
The right approach balances density and reach, using audience quality to validate direction while maximizing efficient, outcome-oriented reach.
4. Healthcare provider and DTC strategies must work in concert.
One of my strongest beliefs in pharmaceutical marketing is that healthcare provider (HCP) and direct-to-consumer (DTC) strategies should operate as a coordinated system, not separate efforts.
In practice, the barriers between the two are rarely strategic. They are organizational, which means budget ownership, disconnected data pipelines, and bureaucratic decision-making prevent coordination.
Organizations that overcome these challenges consistently outperform those that do not.
At MERGE, we have developed a proprietary framework called Performance Link. This coordination is what the fourth principle operationalizes. It orchestrates HCP and DTC investments across new product planning and field force execution. This means when a patient sees an ad for a new drug and asks their doctor about it, the doctor has already received information about that same drug.
Examples include:
- Using HCP engagement and prescribing potential signals to prioritize field force or sales rep investment
- Deploying DTC to unlock demand where HCP adoption has plateaued
- Dynamically shifting spend as doctors move through different stages of adoption
When HCP and DTC budgets and strategy are coordinated, the system becomes more efficient, more responsive, and more outcome driven. Instead of wasted spend, these investments complement each other, improving the chance of a prescription being written.
Where coordination creates advantage.
When outcomes are measured correctly and healthcare provider and consumer strategies operate as a coordinated system, pharmaceutical marketing begins to behave like an integrated growth engine.
But coordination alone is not enough. Even the best strategies struggle if data cannot move effectively between marketers, field teams, and decision-makers.
In the final post of this series, I’ll explore the operational challenges behind many stalled transformation efforts: how data must flow bidirectionally and be designed for real human use to unlock its full value.
If you’re interested in how MERGE helps organizations connect strategy, measurement, and execution through Integrated Outcomes, we’re always open to continuing the discussion.
